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Abstract
Background: Lamin A/C is very important in DNA replication, RNA dependent transcription and
nuclear stabilization. Reduced or absent lamin A/C expression has been found to be a common
feature of a variety of different cancers. To investigate the role of lamin A/C in gastric carcinoma
(GC) pathogenesis, we analyzed the correlations between the lamin A/C expression level and
clinicopathological factors and studied its prognostic role in primary GC.
Methods: The expression of lamin A/C at mRNA level was detected by the reverse transcription-
polymerase chain reaction (RT-PCR) and real time RT-PCR, and western blot was used to examine
the protein expression. Lamin A/C expression and its prognostic significance were investigated by
performing immunohistochemical analysis on a total of 126 GC clinical tissue samples.
Results: Both lamin A/C mRNA and protein expression were downregulated in the majority of
tumours compared with corresponding normal gastric tissues (p  = 0.011 and p  = 0.036,
respectively). Real time RT-PCR further validated that downregulation of lamin A/C is associated
with poor histological differentiation (r = 0.438, p = 0.025). The immunohistochemical staining
showed an evident decrease of lamin A/C expression in 55.6% (70/126) GC cases. Importantly, the
negative lamin A/C expression correlated strongly with histological classification (r = 0.361, p =
0.034). Survival analysis revealed that patients with lamin A/C downregulation have a poorer
prognosis (p = 0.034). In addition, lamin A/C expression was found to be an independent prognostic
factor by multivariate analysis.
Conclusion: Data of this study suggest that lamin A/C is involved in the pathogenesis of GC, and
it may serve as a valuable biomarker for assessing the prognosis for primary GC.
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Background
The A-type lamins (predominantly lamins A and C, two
alternatively spliced products of the LMNA gene), along
with B-type lamins (members of the intermediate fila-
ment proteins), are the most principal components of the
nuclear lamina-a proteinaceous meshwork of 10 nm
diameter filaments lying at the interface between chroma-
tin and the inner nuclear membrane. The nuclear lamina
is thought to be a principal determinant of nuclear archi-
tecture. Downregulation or specific mutations in lamins
cause abnormal nuclear shape, changes in heterochroma-
tin localization at the nuclear periphery, global chromatin
reorganization and possibly specific changes in the posi-
tions of genes [1]. It is possible that changes in the nuclear
lamina and in nuclear shape affect chromatin organiza-
tion and gene positioning, respectively, and in this way
alter patterns of gene expression, contributing to transfor-
mation [2].
Lamin A/C is important in DNA replication, chromatin
anchoring, spatial orientation of nuclear pore complexes,
RNA Pol II-dependent transcription and nuclear stabiliza-
tion [3]. With regard to the multiple functions of A-type
lamins, mutations in the human LMNA gene cause a wide
range of heritable diseases collectively termed laminopa-
thies [4].
Importantly, numerous studies suggest that reduced or
absent lamin A/C expression is a common feature of a
variety of different cancers, including small cell lung can-
cer (SCLC), skin basal cell and squamous cell carcinoma,
testicular germ cell tumour, prostatic carcinoma, leuke-
mia and lymphomas. The reduction in expression of
lamin A/C frequently correlates with cancer subtypes and
cancer aggressiveness, proliferative capacity and differen-
tiation state [5].
Gastric cancer (GC) is the second most common cause of
cancer-related death around the world [6] Although the
number of death of patients undergoing surgical treat-
ment for gastric cancer has decreased recently, GC is still a
major health problem and a leading cause of cancer mor-
tality in Asian countries. To identify reliable prognostic
markers in GC is therefore very important to guide surgi-
cal and chemotherapeutic treatment. It had been reported
that lamin A/C CpG island promoter hypermethylation is
a significant predictor of shorter failure-free survival and
overall survival in nodal diffuse large B-cell lymphomas.
In addition, a series of experiments demonstrated that
Lamin A/C is necessary for the retinoblastoma protein
(pRB) stabilization and decreased expression of lamin A/
C results in reduced activity of pRB. Hence, it is convinci-
ble to presume that change of lamin A/C protein may con-
tribute to tumourigenesis and progression and may be a
biomarker of malignancy. Moss et al [7] had reported that
the expression of lamin A/C was reduced in 7/8 and was
undetectable in 4/8 primary GC by immunohistochemis-
try. However, the change of mRNA level and the clinical
significance of this change remain unknown. We thus
investigated lamin A/C expression in a large amount of
primary GC with RT-PCR, real time RT-PCR, western blot
and immunohistochemistry. Additionally, we identified
its relationship with clinicopathological features and eval-
uated its prognostic value to post-resectional survival in
GC.
Methods
Patients and tissue specimens
A total of 126 primary GC patients treated at the Cancer
Center, Sun Yat-sen University from 2001 to 2002 were
enrolled to this study, including 88 males and 38 females
with a median age of 50 years (range, 21–75 years). All
patients were not pretreated with radiotherapy or chemo-
therapy prior to surgery. With informed consents from
each patient, the matching normal (mucosa far and free
from tumour invasion, > 5 cm) and tumour tissues were
obtained at the time of surgical resection. All tissues were
obtained fresh and frozen in liquid nitrogen until process.
All specimens were confirmed by pathological examina-
tion and staging was performed according to UICC classi-
fication (TNM 1997).
Extraction of total RNA and RT-PCR
Total RNA was extracted from tissues with TRIzol (Invitro-
gen, Carlsbad, CA) according to the user manual. Levels of
lamin A/C mRNA were determined in 52 samples by RT-
PCR and 30 samples by real-time RT-PCR with cDNA pre-
pared from total RNA by using a First Strand cDNA Syn-
thesis kit (Roche, Indianapolis, IN).
For RT-PCR reactions, the thermal cycle was defined at
94°C for 5 min, followed by 30 cycles of denaturing at
94°C for 30 s, annealing at 57.5°C for 30 s and extension
at 72°C for 30 s, and a final extension at 72°C for 10 min.
PCR products were electrophoresed in 1.5% agarose gels
and visualized by ethidium bromide staining to check for
nonspecific amplification. To quantify the densities of the
bands, the gray values were measured with the Bio-Rad
imaging system. After the values of lamin A/C were nor-
malized by the corresponding values of β-actin, the ratio
of the tumour to the non-tumour gastric tissues was calcu-
lated.
For real-time RT-PCR, each reaction was done on a
MX3000P real-time PCR instrument with the SYBR
PremixEx Taq™ (Takara, Dalian, China) in a 25 μl reaction
system with 1 μg cDNA following the manufacturer's pro-
tocol. All reactions were repeated three times. β-actin was
used as an internal control, and measurements between
samples were compared by the threshold cycle of amplifi-Journal of Experimental & Clinical Cancer Research 2009, 28:8 http://www.jeccr.com/content/28/1/8
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cation (CT). The fold change in expression levels was
determined by a comparative CT method using the for-
mula:  ΔΔCT(ΔΔCT = (CT (lamin A/C) - CT (β-action) )cancer - (CT
(lamin A/C) - CT (β-action))normal). Primer sequences used for
lamin A/C are: forward 5'-CGGTTCCCACCAAAGTTCA-3'
and reverse 5'-CTCATCCTCGTCGTCCTCAA-3'; for β-
actin: forward 5'-CACCCAGCACAATGAAGAT-3' and
reverse 5'-CAAATAAAGCCATGCCAAT-3'. The primers
were designed between different exons and encompassing
large introns to avoid any amplification of genomic DNA.
QPCR was performed for pre-denaturing at 95 °C for 10
seconds, followed by 40 cycles (95°C for 5 seconds and
57.5°C for 20 seconds).
Western-blot analysis
Western blot was performed on 34 tumour specimens and
corresponding adjacent non-cancerous samples. The fro-
zen tissues were lysed in RIPA buffer plus protease inhib-
itors PMSF (Sangon, Shanghai, China), and the resulting
insoluble material removed by centrifugation at 12,000 g
4°C for 30 min. After concentration measured by the BCA
method, protein samples were electrophoresed on 12%
sodium dodecyl sulphate (SDS)-polyacrylamide gels and
subsequently transferred to a PVDF membrane (Millipore,
Billerica, MA) by electroblotting. After blocking for 1 h in
Tris buffered saline (pH 7.6, containing 0.1% Tween and
5% non-fat milk) at room temperature, membranes were
incubated overnight at 4°C with primary polyclonal anti-
body against lamin A/C (Cell Signaling, Danvers, MA, at
1:1000 dilution), and β-actin (Abcam, Cambridge, UK, at
1:2000 dilution) with gentle shaking. After washing, the
membrane was then probed with the appropriate second-
ary antibody for 60 min at room temperature. Protein
binding on the membrane was detected by the enhanced
chemiluminescence (ECL) detection system (Pierce, Rock-
ford, IL) according to the manufacturer's instructions.
Then band intensity was measured by densitometry using
the Quantity One software (Bio-Rad, Hercules, CA). The
protein levels were normalized with respect to β-actin pro-
tein level.
Immunohistochemistry analysis
Sections (4 μm thick) of formalin fixed, paraffin wax
blocks were cut onto polylysine-coated microscope slides.
According to the specification of IHC S-P detection kit
(Maixin, Fujian, China): after deparaffinisation in xylene
and hydration through graded alcohol, sections were
washed and then exposed to microwave pretreatment (in
10 mM citrate buffer, pH 6 at 850W for two periods of five
minutes) to enhance antigenicity. Endogenous peroxidase
was blocked with 3% hydrogen peroxide for 10 min and
non-specific binding was blocked with 5% normal goat
serum in phosphate buffered saline for 15 min. Then sec-
tions were incubated with first antibody (rabbit-anti-
human lamin A/C protein polyclonal antibody, Cell Sign-
aling, Danvers, MA) at a concentration of 1: 200 at 4°C
overnight. Biotinylated antirabbit IgG antibody (Boshide,
Wuhan, China) was added for 15 min at 37°C, following
the incubation with streptavidin-biotin/horseradish per-
oxidase complex for 10 min at 37°C. Finally, sections
were colored with 3,3'-diaminobenzidine tetrahydrochlo-
ride (DAB) for 5 min, lightly counterstained with hema-
toxylin and mounted. Sections immunostained with PBS
replacing primary antibody are used as negative control. A
positive control was included with each batch of staining
to ensure consistency between consecutive runs. The
brown-yellow staining of nuclear membrane was consid-
ered positive. For each case, the entire stained tissue sec-
tion was scanned, choosed 5 visual fields at 400×
magnification randomly and count 100 cells each field.
The degree of immunointensity was quantified by using
the total immunostaining score calculated as the sum of
the positive percentage of stained tumour cells and the
staining intensity. The positive percentage was scored as
'0' (< 5%, negative), '1' (5–25%, sporadic), '2' (25–50%,
focal), '3' (> 50%, diffuse). The staining intensity was
score as '0' (no staining), '1' (weakly stained), '2' (moder-
ately stained), and '3' (strongly stained). Cases with
weighted scores of less than 1 were defined as negative;
otherwise they were defined as positive. No folding, and
edging-effect fields were chosen during calculation of 100
cells per five fields. The score assessment was performed
independently by two pathologists.
Statistical analysis
Quantitative values were expressed as means ± SD. Com-
parison of the mRNA and protein expression level of
lamin A/C between tumour and control was made with
Paired-samples  t-test in all cases. Categorical variables
were enumeration data of counting the number of sam-
ples. The correlation of lamin A/C expression with various
clinicopathological parameters was calculated with Chi-
square test for proportion and Pearson's regression analy-
sis. Overall survival was measured from the time of sur-
gery until death with disease, or until the end of follow
up. Patients who died of causes unrelated to the disease
were censored at the time of death. Survival curves were
calculated by the Kaplan-Meier method, and the differ-
ences between the curves were analyzed with the log-rank
test. Cox proportional-hazard analysis was used for uni-
variate and multivariate analysis to explore the effect of
clinicopathological variables and the Lamin A/C expres-
sion on survival. All statistical analyses were performed in
the SPSS 15.0 software and a P value < 0.05 was consid-
ered statistically significant.
Results
RT-PCR and real time RT-PCR analysis
The expression levels of lamin A/C mRNA were examined
in 52 paired clinical samples by semiquantitative RT-PCR.Journal of Experimental & Clinical Cancer Research 2009, 28:8 http://www.jeccr.com/content/28/1/8
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As shown in Fig. 1A, lamin A/C mRNA could be detected
in GC tissues as well as in matched non-cancerous tissues.
However, a large decrease in the levels of lamin A/C
mRNA expression was observed in primary GC as com-
pared with normal tissue. The analysis of results displayed
the density value (normalized to β-actin expression as a
loading control) of tumour was significantly lower than
that in corresponding non-cancerous tissue using paired t-
test (p = 0.011, Fig. 1B).
To validate the results of semiquantitative RT-PCR, we
randomly selected 30 cases out of the 52 patients to inves-
tigate the mRNA expression level with real time RT-PCR.
The dissociation curve and amplification curve were
shown in Fig. 2A and 2B. The fold change in expression
Expression pattern of lamin A/C in GC specimens by RT-PCR Figure 1
Expression pattern of lamin A/C in GC specimens by RT-PCR. (A) 1.5% agarose electrophoresis of lamin A/C prod-
ucts of RT-PCR in GC specimens. Representative results from 4 pairs of GC and corresponding normal gastric tissues are 
shown. β-actin was used as an internal quantitative control. (B) Densitometry analyses of lamin A/C mRNA level quantified by 
compared with β-actin in GC and corresponding normal gastric samples. The expression of lamin A/C gene was reduced in 
tumour tissues when compared with corresponding non-tumourous tissues (p = 0.011). T, GC; N, corresponding non-cancer-
ous tissues.Journal of Experimental & Clinical Cancer Research 2009, 28:8 http://www.jeccr.com/content/28/1/8
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levels determined by a comparative CT method also dem-
onstrated that lamin A/C expression is reduced in GC tis-
sues. We further analyzed the correlations between lamin
A/C mRNA expression and clinicopathological features.
As shown in Table 1, the mRNA expression level was evi-
dently lower in poor differentiated tumours than that in
well or moderately differentiated tumours. Decreased of
lamin A/C expression correlated with histological differ-
entiation significantly (r = 0.438, p = 0.025). However,
there were no statistical correlations between lamin A/C
and invasion, tumour size and metastasis.
Western blot analysis
Western blot was performed on 34 tumour specimens and
corresponding adjacent non-cancerous samples to further
investigate if the expression of lamin A/C is reduced at
protein levels. Western blot showed a lamin A/C band at
the expected 70 kDa size and the amount of lamin A/C
protein was measured by densitometry. Lamin A/C pro-
tein expression was decreased in 47% (16/34) of gastric
cancer tissues in comparison with the adjacent normal tis-
sues, as shown in Figure 3A. The 16 cases of reduced lamin
A/C protein level of cancerous gastric tissues compared
with the normal matched tissues included 13 cases with
reduced expression on mRNA level and 3 cases even with-
out the transcriptional reduction. The analysis of results
displayed that the density value (normalized to β-actin
expression as a loading control) of tumour was signifi-
cantly lower than that of corresponding noncancerous tis-
sue (P = 0.036) (Fig. 3B). These data are in agreement with
the results from the RT-PCR analysis for lamin A/C expres-
sion in patients with gastric cancer.
Immunohistochemistry analysis
Lamin A/C immunostaining were strong brown-yellow in
96% (121/126) normal gastric mucosal epithelial cells,
with location to nuclear membrane, while only 4% (5/
126) samples were negative(Figure 4A). However, in
tumour tissues, the positive rate of lamin A/C protein
expression was only 55.6% (70/126), while negative rate
was 44.4% (56/126) (Fig. 4B, C and 4D). We often
observed a sharp contrast between infiltrative tumour
areas of negative staining and the adjacent tissue of posi-
tive staining (Fig. 4D). Compared with normal tissues,
there is evident weaken of lamin A/C immunoreactivity in
GC samples with significant difference (p = 0.016). We
also did an analysis concerning the correlation between
the expression of lamin A/C and the clinicopathological
variables. As shown in Table 1, the positive rate of lamin
A/C expression was 78.9%, 65.1%, 51.6% and 35% in
well-differentiated, moderately-differentiated, poorly-dif-
ferentiated adenocarcinoma and undifferentiated carci-
noma, respectively. There was a significant difference
between histological type and expression of lamin A/C,
the lower the differentiation, the more the absence of
lamin A/C presence(r = 0.361, p = 0.034). There was no
apparent relevance between lamin A/C protein expression
and patient gender, age, tumour size, distant metastasis,
lymph node involvement, the depth of invasion or clini-
cal staging (P > 0.05 respectively)(Table 2).
Correlation between lamin A/C expression and patients' 
survival
Using Kaplan-Meier curve method, we evaluated the rela-
tionship between the lamin A/C expression and the out-
come of 126 patients. The overall survival rates were
58.6% and 44.6%, respectively, in patients with positive
and negative lamin A/C expression. Of 70 lamin A/C
immunohistochemical positive-staining patients, the
median survival time is 45.0 ± 5.5 months, while that of
56 negative-staining patients is 26.0 ± 4.2 months. There
was a significantly longer median survival time in the
lamin A/C protein-positive group than in the negative
group (P = 0.034, log-rank test; Fig. 5). Univariate Cox
regression analysis also identified that clinical variables
including tumour invasion and metastasis were signifi-
Table 1: Correlations between lamin A/C expression detected by real time RT-PCR and pathological variables in 30 cases of GC
Variables Number of Cases Fold Change (mean ± SD) t p-Value
Invasion
Profound layer 24 0.77 ± 0.19 -0.692 0.495
Superficial layer 6 0.83 ± 0.19
Differentiation
Poor 21 0.73 ± 0.19 -2.376 0.025a
Well or Moderate 9 0.90 ± 0.13
Metastasis
No 23 0.76 ± 0.18 -0.792 0.435
Yes 7 0.83 ± 0.23
Tumour Size (cm)
< 5 18 0.83 ± 0.18 1.704 0.099
≥5 12 0.71 ± 0.20
a Statistically significant (p < 0.05).Journal of Experimental & Clinical Cancer Research 2009, 28:8 http://www.jeccr.com/content/28/1/8
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cantly associated with overall survival (Table 3). Further-
more, to evaluate the potential of negative lamin A/C
expression (negative vs. positive) as an independent pre-
dictor for overall survival of GC, multivariate Cox regres-
sion analyses were performed. While tumour invasion
failed to demonstrate independency, only status of metas-
tasis and negative lamin A/C expression may play a role to
predict the overall survival in GC (p = 0.040 and p = 0.041,
respectively; Table 3).
Discussion
A-type lamins are essential components of the nuclear
lamina [8]. Aside from their structural role in the forma-
tion of the nuclear lamina, lamins A and C are found in
the nucleoplasm adjacent to sites of DNA synthesis and
RNA processing, suggesting that these proteins could
influence both DNA replication and gene expression [2-
4]. The A-type lamins, lamins A and C, are synthesized
from alternatively spliced transcripts of lamin A gene
(LMNA) [9,10]. A-type lamins are absent in early embry-
onic development and in certain stem cell populations in
adults [11-13] and are expressed only after commitment
of cells to a particular differentiation pathway [12,14].
Mutations in LMNA produce an intriguingly diverse spec-
trum of diseases including muscular dystrophies (Emery-
Dreifuss muscular dystrophy, limb-girdle muscular dys-
trophy type 1B), neuropathy (Charcot-Marie-Tooth dis-
ease type 2), dilated cardiomyopathy with conduction
system disease, familial partial lipodystrophy (s.c. fat loss
and diabetes), mandibuloacral dysplasia (skeletal malfor-
mations and lipodystrophy), atypical Werner's syndrome,
and Hutchinson-Gilford progeria syndrome(precocious
aging syndromes) [15-19]. To date, some 200 mutations
have been identified in LMNA.
The dissociation curves and amplification curves of lamin A/C in GC specimens by real time RT-PCR Figure 2
The dissociation curves and amplification curves of lamin A/C in GC specimens by real time RT-PCR. Repre-
sentative results from 5 pairs of GC and corresponding normal gastric tissues are shown. (A) The dissociation curves of lamin 
A/C and β-actin. (B) The amplification curves of lamin A/C and β-actin.
A
   -actin Lamin A/C
B
   -actin Lamin A/C
Figure 2Journal of Experimental & Clinical Cancer Research 2009, 28:8 http://www.jeccr.com/content/28/1/8
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Numerous studies have shown that reduced or absent
lamin A/C expression is a common feature of a variety of
different cancers, notwithstanding there is little direct evi-
dence connecting tumourigenesis to A-type lamins
[5,7,20-23]. Besides maintain the normal nuclear struc-
ture, the lamins and lamin-associated proteins are also
required for most other nuclear activities including DNA
replication, RNA Pol II-dependent transcription, migra-
tion and anchorage of nuclei, correct spacing of nuclear
pore complexes, regulation of mitosis, and apoptosis [3].
With respect to its multiple functions, it is convincible to
presume that change of lamin A/C protein may contribute
to tumourigenesis and progression.
The development of GC is a multistep process and pheno-
typic changes during cancer progression reflect the
sequential accumulation of genetic alterations in cells.
Carcinogenesis and progression of human GC are related
to the activation of proto-oncogenes and/or the inactiva-
tion of tumour suppressor genes. Moss et al [7] detected
the expression of lamin A/C in 8 primary GC patients by
immunohistochemistry, they found reduced expression
of lamin A/C in 7/8 patients. The case number studied in
that report was relatively small, and the change of mRNA
level and the clinical significance of this change were not
investigated. We did this study on over one hundred cases
of primary GC to elucidate the expression change of lamin
A/C and its clinicopathological correlation. This study
clearly showed that lamin A/C mRNA as well as protein
was down-regulated in GC tissues compared with the
adjacent normal tissues, suggesting that lower expression
of lamin A/C occurred not only at the post-transcriptional
level, but also at the transcriptional level in GC samples.
In addition, correlation analysis based on real time RT-
PCR revealed that lamin A/C mRNA expression is associ-
ated with histological differentiation in GC.
Expression pattern of lamin A/C in GC specimens by Western Blot Figure 3
Expression pattern of lamin A/C in GC specimens by Western Blot. (A) Representative results from 4 pairs of GC 
and corresponding normal gastric tissues are shown. β-actin was used as an internal quantitative control. (B) Densitometry 
analyses of lamin A/C protein level quantified by compared with β-actin in GC and corresponding normal gastric samples. The 
expression of lamin A/C gene was reduced in tumour tissues when compared with corresponding non-tumourous tissues (p = 
0.036). T, GC; N, corresponding non-cancerous tissues.Journal of Experimental & Clinical Cancer Research 2009, 28:8 http://www.jeccr.com/content/28/1/8
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Furthermore, we examined the expression of lamin A/C in
primary gastric cancer and their relationships with clinico-
pathological characteristics. Compared with only 4% (5/
126) negative staining in normal gastric samples, there
was a higher negative rate of 44.4% (56/126) in tumour
tissues. Compared with normal tissues, there is evident
weaken of lamin A/C immunoreactivity in GC samples
with significant difference (p = 0.016). In addition, statis-
tical analysis demonstrated an evident correlation
between expression of lamin A/C and histological type.
With the progression of tumour, the percentage of nega-
tive lamin A/C expression was also growing, which is con-
sistent with previous conclusion that lamin A/C is
expressed only in later stages of development and in dif-
ferentiated cells. The low expression of lamin A/C mRNA
and protein observed in gastric carcinoma suggests that
loss of lamin A/C involves in the development of human
gastric carcinoma.
A number of groups have reported that A-type lamins, in
contrast to B-type lamins, are differentially expressed in
embryonic tissues [12,13,24]. Undifferentiated cells or
cells at early stages of differentiation were found to lack A-
type lamin expression. In addition, A-type lamins were
not expressed in proliferating cells of some adult human
tissues such as the basal keratinocytes of the skin[25]. This
could probably explain why more poorly differentiated
gastric tumour tissues lack lamin A/C expression.
Table 2: Association of Lamin A/C immunostaining with clinicopathological parameters in 126 cases of primary GC
Clinicopathological variable Cases (n = 126) Lamin A/C p-value
positive (%) negative (%)
n = 70 n = 56
Gender 0.410
male 88 51 (58.0) 37 (42.0)
female 38 19 (50.0) 19 (50.0)
Age (years)a 0.905
< 56 60 33 (55.0) 27 (45.0)
≥ 56 66 37 (56.1) 29 (43.9)
Tumour size (cm)a 0.902
< 5 78 43 (55.1) 35 (44.9)
≥ 5 48 27 (56.3) 21 (43.7)
Depth of invasion 0.870
T1 9 6 (66.7) 3 (33.3)
T2 22 12 (54.5) 10 (45.5)
T3 75 42(56.0) 33 (44.0)
T4 20 10 (50.0) 10 (50.0)
Lymph node metastasisb 0.550
N0 42 23 (54.8) 19 (45.2)
N1 36 22 (61.1) 14 (38.9)
N2 38 18 (47.4) 20(52.6)
N3 10 7(70.0) 3 (30.0)
Distant metastasis 0.659
M0 101 55 (54.5) 40 (45.5)
M1 25 15(60.0) 10 (40.0)
Staging 0.894
I 17 10 (58.8) 7 (41.2)
II 27 14 (51.9) 13 (48.1)
III 47 25 (53.2) 22 (46.8)
IV 35 21 (60.0) 14 (40.0)
Differentiation 0.034c
well 19 15(78.9) 4 (21.1)
moderate 20 13(65.0) 7 (35.0)
poor 67 35(51.6) 32 (48.4)
undifferentiated 20 7 (35.0) 13 (65.0)
agrouping of age and tumour size was performed according to median.
b grouping of staging and lymph node metastasis was performed according to UICC classification (TNM 1997).
cstatistical significance (p < 0.05)Journal of Experimental & Clinical Cancer Research 2009, 28:8 http://www.jeccr.com/content/28/1/8
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Another important discovery in our study was that
decreased expressions of lamin A/C was significantly cor-
related with poor patient outcome. Patients with gastric
cancer who were lamin A/C protein-negative had a worse
5-year survival rate. Although there has been a great
improvement in the diagnosis and treatment with gastric
cancer recently, it is still a major health problem and a
leading cause of cancer mortality in Asian countries. To
identify reliable prognostic markers in gastric cancer is
therefore very important to guide surgical and chemother-
apeutic treatment according to individual risk. This find-
ing suggested that lamin A/C may have diagnostic and
therapeutic potential for patients with gastric cancer in
order to design optimal individual treatment modalities.
The mechanism of tumour suppression by lamin A/C is
not fully understood. Biochemical studies have shown
that lamin A/C can interact with different gene regulators
including SREBP1, MOK2 and the retinoblastoma protein
(pRB) [26-28]. Excitingly, a series of experiments demon-
strated that lamin A/C is necessary for a generally known
tumour suppressor – pRB stabilization, and decreased
expression of lamin A/C results in reduced activity of pRB
[29-31]. pRB is a critical regulator of cell proliferation and
Immunohistochemical detection of Lamin A/C protein expression in GC and surrouding non-cancerous tissues Figure 4
Immunohistochemical detection of Lamin A/C protein expression in GC and surrouding non-cancerous tis-
sues. Positive staining was mostly seen on nuclear of epithelial cells. (A) positive staining of Lamin A/C in normal gastric 
mucosa(× 100). (B) negative staining of Lamin A/C in well-differentiated gastric carcinoma(× 100). (C) negative staining of 
Lamin A/C in moderately differentiated gastric carcinoma(× 100). (D) negative staining of Lamin A/C in gastric signet-ring cell 
carcinoma(× 100). T, GC; N, corresponding non-cancerous tissues. The right upper frame of each figure showing high-power 
field(× 400).Journal of Experimental & Clinical Cancer Research 2009, 28:8 http://www.jeccr.com/content/28/1/8
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differentiation and an important tumor suppressor. In the
G(1) phase of the cell cycle, pRB localizes to perinucleolar
sites associated with lamin A/C intranuclear foci. Johnson
et al[32] examined pRB function in cells lacking lamin A/
C, finding that pRB levels are evidently decreased and that
the remaining pRB is mislocalized. They demonstrated
that A-type lamins protect pRB from proteasomal degra-
dation. Both pRB levels and localization are restored upon
reintroduction of lamin A. Lmna(-/-) cells resemble Rb(-/
-) cells, exhibiting altered cell-cycle properties and
reduced capacity to undergo cell-cycle arrest in response
to DNA damage. Their findings established a functional
link between a core nuclear structural component and an
important cell-cycle regulator. Recently, there was another
report showing that protein levels of the oncoprotein
gankyrin are elevated in Lmna-/- fibroblasts and Lmna-/-
cells are refractory to p14arf-mediated cell cycle arrest, as
was previously shown with p16ink4a [33]. These findings
together with our data increase the possibility that lamin
A/C might function as a tumour suppressor through func-
tion as a negative regulator of cell growth.
However, the molecular mechanism underlying the loss
of lamin A/C in human cancer remains unknown. Tran-
scriptional inactivation by CpG island promoter hyper-
methylation is a well-established mechanism for gene
silencing in human tumours and may represent a frequent
mechanism by which the gene is inactivated during
tumourigenesis [34]. Methylation of the promoter region
is an alternative mechanism to intragenic mutations for
Table 3: The overall survival univariate and multivariate Cox 
regression analysis
Clinicopathological Variable Relative Risk (95% CI) p-Value
Univariate
Gender 0.948 (0.549–1.637) 0.038
Tumour Size 1.621 (0.974–2.697) 0.063
Metastasis 2.057 (1.110–3.810) 0.022 a
Invasion 2.012 (1.098–3.698) 0.024a
Stage 0.915 (0.709–1.181) 0.497
Histological Differentiation 1.704 (0.969–2.997) 0.064
Lamin A/C 0.582 (0.349–0.969) 0.038a
Multivariate
Metastasis 1.905 (1.029–3.526) 0.040a
Lamin A/C 0.585 (0.350–0.978) 0.041a
Abbreviation: 95% CI, 95% confidence interval.
a Statistically significant (p < 0.05).
Estimated overall survival according to the expression of lamin A/C in 126 cases of GCs (the Kaplan – Meier method) Figure 5
Estimated overall survival according to the expression of lamin A/C in 126 cases of GCs (the Kaplan – Meier 
method). Based on the results of immunohistochemical staining, the expression of lamin A/C was classified as the negative 
expression (n = 56) and the positive (n = 70). Log-rank test shows that GC patients with the negative lamin A/C expression 
showed significantly poorer prognosis than those with the positive expression.Journal of Experimental & Clinical Cancer Research 2009, 28:8 http://www.jeccr.com/content/28/1/8
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the inactivation of tumour suppressor genes and plays an
important role in tumourigenesis [35]. Classical tumour
suppressor genes and genes involved in chemosensitivity,
such as hMLH1, p16, p15, Rb, VHL, E-cadherin, GSTP1,
and BRCA1, or the DNA repair gene MGMT, undergo epi-
genetic inactivation by hypermethylation of their regula-
tory regions [36-39]. Researchers demonstrated the
presence of promoter CpG island hypermethylation in
lamin A/C gene and correlated this to loss of mRNA and
protein expression in leukemia and lymphoma malignan-
cies [40]. Furthermore, they also reported that lamin A/C
CpG island promoter hypermethylation is a significant
predictor of shorter failure-free survival and overall sur-
vival in nodal diffuse large B-cell lymphomas. This epige-
netic alteration could explain why somatic mutation of
lamin A/C was not detected in cancer cells.
Conclusion
We found a significant lower lamin A/C expression level
in gastric cancer tissues compared with non-cancerous
gastric tissues, and loss of lamin A/C expression correlates
with histological classification. Our results suggest lamin
A/C may play a suppressive role in tumourigenesis of gas-
tric cancer. Lamin A/C could serve as a useful prognostic
marker in primary gastric cancer patients and a therapeu-
tic target to prevent gastric carcinoma. However, to eluci-
date the molecular mechanisms of lamin A/C in gastric
carcinogenesis, further studies are still needed to be done.
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